rs587779065
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000251.3(MSH2):c.1013G>A(p.Gly338Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000685 in 1,460,120 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G338R) has been classified as Pathogenic.
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.1013G>A | p.Gly338Glu | missense_variant | 6/16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.1013G>A | p.Gly338Glu | missense_variant | 6/16 | 1 | NM_000251.3 | ENSP00000233146.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460120Hom.: 0 Cov.: 29 AF XY: 0.00000138 AC XY: 1AN XY: 726548
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch-like syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Constitutional Genetics Lab, Leon Berard Cancer Center | Jul 01, 2019 | - - |
Lynch syndrome Pathogenic:1
Pathogenic, reviewed by expert panel | research | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Sep 05, 2013 | Multifactorial likelihood analysis posterior probability >0.99 - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 24, 2020 | The p.G338E pathogenic mutation (also known as c.1013G>A), located in coding exon 6 of the MSH2 gene, results from a G to A substitution at nucleotide position 1013. The glycine at codon 338 is replaced by glutamic acid, an amino acid with similar properties. This variant was identified in a male proband who met Amsterdam I criteria for Lynch syndrome and was diagnosed with bladder cancer at the age of 57 as well as MSI-H colon cancer cancer at the of age 32 that demonstrated loss of both MSH2/MSH6 staining on immunohistochemistry (IHC) (Raskin L et al. Oncotarget, 2017 Nov;8:93450-93463). Based on an internal structural analysis, this variant is anticipated to result in a significant decrease in structural stability (Warren JJ et al. Mol Cell, 2007 May;26:579-92). Another alteration at the same codon, p.G338R (c.1012G>C), has been detected in individuals with family histories that met Amsterdam I/II criteria and/or had Lynch syndrome associated tumors that demonstrated loss of MSH2/MSH6 staining on IHC (Ambry internal data; Moline J et al, Gynecol. Oncol. 2013 Jul; 130(1):121-6; Pearlman R et al. J. Med. Genet., 2019 Jul;56:462-470). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at